Loading...

We've got a brand new version of Simply Wall St! Try it out

Vistin Pharma

OB:VISTIN
Snowflake Description

Flawless balance sheet with moderate growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
VISTIN
OB
NOK426M
Market Cap
  1. Home
  2. NO
  3. Pharmaceuticals & Biotech
Company description

Vistin Pharma ASA, through its subsidiary, Vistin Pharma AS, produces and sells metformin active pharmaceutical ingredients and direct compressible granulates for the pharmaceutical industry worldwide. The last earnings update was 16 days ago. More info.


Add to Portfolio Compare Print
  • Vistin Pharma has significant price volatility in the past 3 months.
VISTIN Share Price and Events
7 Day Returns
9.3%
OB:VISTIN
-2.2%
Europe Pharmaceuticals
2.6%
NO Market
1 Year Returns
-12.7%
OB:VISTIN
6.8%
Europe Pharmaceuticals
-9.1%
NO Market
VISTIN Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Vistin Pharma (VISTIN) 9.3% 43.3% 37.5% -12.7% -66.2% -
Europe Pharmaceuticals -2.2% 0.5% 2.3% 6.8% 10.1% 3.1%
NO Market 2.6% 8% 2.6% -9.1% 31.3% 13.2%
1 Year Return vs Industry and Market
  • VISTIN underperformed the Pharmaceuticals industry which returned 6.8% over the past year.
  • VISTIN underperformed the Market in Norway which returned -9.1% over the past year.
Price Volatility
VISTIN
Industry
5yr Volatility vs Market

VISTIN Value

 Is Vistin Pharma undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Vistin Pharma. This is due to cash flow or dividend data being unavailable. The share price is NOK9.6.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Vistin Pharma's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Vistin Pharma's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
OB:VISTIN PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-06-30) in NOK NOK-1.27
OB:VISTIN Share Price ** OB (2019-09-13) in NOK NOK9.6
Europe Pharmaceuticals Industry PE Ratio Median Figure of 54 Publicly-Listed Pharmaceuticals Companies 23.94x
Norway Market PE Ratio Median Figure of 149 Publicly-Listed Companies 13.32x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Vistin Pharma.

OB:VISTIN PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= OB:VISTIN Share Price ÷ EPS (both in NOK)

= 9.6 ÷ -1.27

-7.56x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Vistin Pharma is loss making, we can't compare its value to the Europe Pharmaceuticals industry average.
  • Vistin Pharma is loss making, we can't compare the value of its earnings to the Norway market.
Price based on expected Growth
Does Vistin Pharma's expected growth come at a high price?
Raw Data
OB:VISTIN PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -7.56x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
46.6%per year
Europe Pharmaceuticals Industry PEG Ratio Median Figure of 38 Publicly-Listed Pharmaceuticals Companies 1.78x
Norway Market PEG Ratio Median Figure of 110 Publicly-Listed Companies 0.72x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Vistin Pharma, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Vistin Pharma's assets?
Raw Data
OB:VISTIN PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-06-30) in NOK NOK7.86
OB:VISTIN Share Price * OB (2019-09-13) in NOK NOK9.6
Europe Pharmaceuticals Industry PB Ratio Median Figure of 115 Publicly-Listed Pharmaceuticals Companies 2.87x
Norway Market PB Ratio Median Figure of 238 Publicly-Listed Companies 1.13x
OB:VISTIN PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= OB:VISTIN Share Price ÷ Book Value per Share (both in NOK)

= 9.6 ÷ 7.86

1.22x

* Primary Listing of Vistin Pharma.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Vistin Pharma is good value based on assets compared to the Europe Pharmaceuticals industry average.
X
Value checks
We assess Vistin Pharma's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Pharmaceuticals industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Pharmaceuticals industry average (and greater than 0)? (1 check)
  5. Vistin Pharma has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

VISTIN Future Performance

 How is Vistin Pharma expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

  • No analysts cover Vistin Pharma, future earnings growth has been estimated based on fundamentals.
The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
46.6%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Vistin Pharma expected to grow at an attractive rate?
  • Vistin Pharma's earnings growth is expected to exceed the low risk savings rate of 1.8%.
Growth vs Market Checks
  • Vistin Pharma's earnings growth is expected to exceed the Norway market average.
  • Unable to compare Vistin Pharma's revenue growth to the Norway market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
OB:VISTIN Future Growth Rates Data Sources
Data Point Source Value (per year)
OB:VISTIN Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts 46.6%
Europe Pharmaceuticals Industry Earnings Growth Rate Market Cap Weighted Average 13.3%
Europe Pharmaceuticals Industry Revenue Growth Rate Market Cap Weighted Average 4.7%
Norway Market Earnings Growth Rate Market Cap Weighted Average 15.1%
Norway Market Revenue Growth Rate Market Cap Weighted Average 4%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
OB:VISTIN Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in NOK Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
OB:VISTIN Future Estimates Data
Date (Data in NOK Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
OB:VISTIN Past Financials Data
Date (Data in NOK Millions) Revenue Cash Flow Net Income *
2019-06-30 196 -24 -59
2019-03-31 190 -32 -70
2018-12-31 201 -39 -68
2018-09-30 202 -5 -16
2018-06-30 194 -22 -8
2018-03-31 186 13 8
2017-12-31 175 10 5
2017-09-30 168 6 10
2017-06-30 160 41 7
2017-03-31 170 25 14
2016-12-31 173 54 16
2016-09-30 393 100 40

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Vistin Pharma's earnings are expected to grow significantly at over 20% yearly.
  • Unable to determine if Vistin Pharma is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
OB:VISTIN Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from Vistin Pharma Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

OB:VISTIN Future Estimates Data
Date (Data in NOK Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
OB:VISTIN Past Financials Data
Date (Data in NOK Millions) EPS *
2019-06-30 -1.27
2019-03-31 -1.73
2018-12-31 -1.92
2018-09-30 -0.57
2018-06-30 -0.35
2018-03-31 0.50
2017-12-31 0.32
2017-09-30 0.56
2017-06-30 0.41
2017-03-31 0.83
2016-12-31 0.93
2016-09-30 2.36

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Vistin Pharma will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Vistin Pharma's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Europe market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Europe market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Vistin Pharma has a total score of 3/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

VISTIN Past Performance

  How has Vistin Pharma performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Vistin Pharma's growth in the last year to its industry (Pharmaceuticals).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Vistin Pharma does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Vistin Pharma's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Vistin Pharma's 1-year growth to the Europe Pharmaceuticals industry average as it is not currently profitable.
Earnings and Revenue History
Vistin Pharma's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Vistin Pharma Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

OB:VISTIN Past Revenue, Cash Flow and Net Income Data
Date (Data in NOK Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-06-30 196.44 -58.96 69.27
2019-03-31 189.94 -69.68 68.62
2018-12-31 200.51 -67.69 69.58
2018-09-30 201.60 -16.08 69.69
2018-06-30 193.78 -7.52 64.96
2018-03-31 186.44 8.48 61.87
2017-12-31 175.06 5.45 58.19
2017-09-30 167.89 9.56 50.34
2017-06-30 160.49 7.05 49.05
2017-03-31 169.80 14.04 48.20
2016-12-31 173.26 15.94 46.90
2016-09-30 393.25 40.31 104.63
2016-06-30 445.91 46.20 122.61
2015-12-31 375.81 32.78 108.45
2014-12-31 361.46 -61.60 96.20
2013-12-31 347.25 8.39 94.41

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Vistin Pharma has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Vistin Pharma has efficiently used its assets last year compared to the Europe Pharmaceuticals industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Vistin Pharma improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Vistin Pharma's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Pharmaceuticals industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Vistin Pharma has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

VISTIN Health

 How is Vistin Pharma's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Vistin Pharma's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Vistin Pharma is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Vistin Pharma's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Vistin Pharma's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Vistin Pharma has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Vistin Pharma Company Filings, last reported 2 months ago.

OB:VISTIN Past Debt and Equity Data
Date (Data in NOK Millions) Total Equity Total Debt Cash & Short Term Investments
2019-06-30 348.49 0.00 290.71
2019-03-31 348.06 0.00 299.55
2018-12-31 348.85 0.00 320.73
2018-09-30 409.91 0.00 330.58
2018-06-30 412.06 0.00 333.66
2018-03-31 126.00 0.00 59.39
2017-12-31 120.16 0.00 85.34
2017-09-30 182.21 0.00 33.52
2017-06-30 179.01 0.00 59.71
2017-03-31 190.51 0.00 66.09
2016-12-31 186.61 0.00 89.44
2016-09-30 194.39 0.00 72.71
2016-06-30 190.12 0.00 55.71
2015-12-31 183.92 0.00 61.99
2014-12-31 127.98 0.00
2013-12-31 199.78 0.00
  • Vistin Pharma has no debt.
  • Vistin Pharma has not taken on any debt in the past 5 years.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Vistin Pharma has sufficient cash runway for more than 3 years based on current free cash flow.
  • Vistin Pharma has sufficient cash runway for more than 3 years if free cash flow continues to grow at historical rates of 104% each year.
X
Financial health checks
We assess Vistin Pharma's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Vistin Pharma has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

VISTIN Dividends

 What is Vistin Pharma's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Vistin Pharma dividends.
If you bought NOK2,000 of Vistin Pharma shares you are expected to receive NOK0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Vistin Pharma's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Vistin Pharma's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
OB:VISTIN Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
Europe Pharmaceuticals Industry Average Dividend Yield Market Cap Weighted Average of 39 Stocks 3%
Norway Market Average Dividend Yield Market Cap Weighted Average of 115 Stocks 4.5%
Norway Minimum Threshold Dividend Yield 10th Percentile 1.5%
Norway Bottom 25% Dividend Yield 25th Percentile 2.5%
Norway Top 25% Dividend Yield 75th Percentile 6.5%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

OB:VISTIN Future Dividends Estimate Data
Date (Data in NOK) Dividend per Share (annual) Avg. No. Analysts
OB:VISTIN Past Annualized Dividends Data
Date (Data in NOK) Dividend per share (annual) Avg. Yield (%)
2019-08-29 0.000 0.000
2019-04-25 0.000 0.000
2019-02-19 0.000 0.000
2018-10-25 0.000 0.000
2018-08-30 0.000 0.000
2018-04-26 0.000 0.000
2018-04-16 0.000 0.000
2018-02-27 0.000 0.000
2017-04-25 1.000 5.713
2016-04-28 0.600 2.498

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Vistin Pharma has not reported any payouts.
  • Unable to verify if Vistin Pharma's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Vistin Pharma's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Vistin Pharma has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Vistin Pharma's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.5%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Vistin Pharma afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Vistin Pharma has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

VISTIN Management

 What is the CEO of Vistin Pharma's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Kjell-Erik Nordby
COMPENSATION NOK4,510,000
AGE 62
TENURE AS CEO 4.3 years
CEO Bio

Mr. Kjell-Erik Nordby, M.Sc., M.B.A., has been the Chief Executive Officer of Vistin Pharma ASA since June 1, 2015. Mr. Nordby served as the Chief Executive Officer of Weifa ASA from February 2009 to June 1, 2015. He served as Chief Executive Officer of Weifa AS since February 2009. He served as Vice President and Director of Business Development of PCI Biotech Holding ASA (formerly known as Photocure ASA) since April 2007. Mr. Nordby has an extensive experience in business development, marketing and sales. He served at Alpharma (API Business Development) as the Vice President of Sales & Marketing of North Europe and served as its Senior Director for Business Development and Project Portfolio Management. He served as a Director of Navamedic ASA since May 2012. He holds an MBA of Honor from the Norwegian School of Management, a degree in International Marketing from the Norwegian School of Management and a Master of Science in Pharmacy from the University of Oslo.

CEO Compensation
  • Kjell-Erik's compensation has been consistent with company performance over the past year, both up more than 20%.
  • Kjell-Erik's remuneration is higher than average for companies of similar size in Norway.
Management Team Tenure

Average tenure of the Vistin Pharma management team in years:

4.3
Average Tenure
  • The tenure for the Vistin Pharma management team is about average.
Management Team

Kjell-Erik Nordby

TITLE
Chief Executive Officer
COMPENSATION
NOK5M
AGE
62
TENURE
4.3 yrs

Gunnar Manum

TITLE
Chief Financial Officer
COMPENSATION
NOK2M
AGE
54
TENURE
4.3 yrs

Valborg Vold

TITLE
Chief Operating Officer
COMPENSATION
NOK2M
TENURE
1.9 yrs
Board of Directors Tenure

Average tenure and age of the Vistin Pharma board of directors in years:

2.1
Average Tenure
57
Average Age
  • The average tenure for the Vistin Pharma board of directors is less than 3 years, this suggests a new board.
Board of Directors

Ole Enger

TITLE
Chairman
COMPENSATION
NOK750K
AGE
71

Øystein Spetalen

TITLE
Director
COMPENSATION
NOK70K
AGE
57
TENURE
4.7 yrs

Åse Musum

TITLE
Employee Representative Director
COMPENSATION
NOK150K
TENURE
4.7 yrs

Mimi Berdal

TITLE
Director
COMPENSATION
NOK150K
AGE
60
TENURE
2.3 yrs

Bettina Banoun

TITLE
Director
AGE
47
TENURE
1.3 yrs

Finn-Bjørn Ruyter

TITLE
Director
AGE
55
TENURE
1.3 yrs

Espen Gregoriussen

TITLE
Employee Representative Director
COMPENSATION
NOK5K
TENURE
1.9 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (NOK) Value (NOK)
23. Nov 18 Sell Valborg Vold Individual 18. Sep 18 18. Sep 18 -50,000 NOK10.58 NOK-529,000
X
Management checks
We assess Vistin Pharma's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Vistin Pharma has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

VISTIN News

Simply Wall St News

Does Vistin Pharma ASA's (OB:VISTIN) CEO Salary Reflect Performance?

See our latest analysis for Vistin Pharma How Does Kjell-Erik Nordby's Compensation Compare With Similar Sized Companies? … It would therefore appear that Vistin Pharma ASA pays Kjell-Erik Nordby more than the median CEO remuneration at companies of a similar size, in the same market. … We compared total CEO remuneration at Vistin Pharma ASA with the amount paid at companies with a similar market capitalization.

Simply Wall St -

Have Insiders Been Selling Vistin Pharma ASA (OB:VISTIN) Shares This Year?

So before you buy or sell Vistin Pharma ASA (OB:VISTIN), you may well want to know whether insiders have been buying or selling. … Check out our latest analysis for Vistin Pharma The Last 12 Months Of Insider Transactions At Vistin Pharma The Chief Operating Officer, Valborg Vold, made the biggest insider sale in the last 12 months. … OB:VISTIN Recent Insider Trading, July 19th 2019 Insider Ownership of Vistin Pharma For a common shareholder, it is worth checking how many shares are held by company insiders.

Simply Wall St -

What Kind Of Shareholders Own Vistin Pharma ASA (OB:VISTIN)?

Every investor in Vistin Pharma ASA (OB:VISTIN) should be aware of the most powerful shareholder groups. … Check out our latest analysis for Vistin Pharma OB:VISTIN Ownership Summary, May 30th 2019 What Does The Institutional Ownership Tell Us About Vistin Pharma? … Insider Ownership Of Vistin Pharma The definition of an insider can differ slightly between different countries, but members of the board of directors always count.

Simply Wall St -

Is Vistin Pharma ASA's (OB:VISTIN) CEO Salary Justified?

Kjell-Erik Nordby has been the CEO of Vistin Pharma ASA (OB:VISTIN) since 2015. … This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. … How Does Kjell-Erik Nordby's Compensation Compare With Similar Sized Companies?

Simply Wall St -

How Much Are Vistin Pharma ASA (OB:VISTIN) Insiders Taking Off The Table?

So shareholders might well want to know whether insiders have been buying or selling shares in Vistin Pharma ASA (OB:VISTIN). … But logic dictates you should pay some attention to whether insiders are buying or selling shares. … Vistin Pharma Insider Transactions Over The Last Year.

Simply Wall St -

What Kind Of Investor Owns Most Of Vistin Pharma ASA (OB:VISTIN)?

If you want to know who really controls Vistin Pharma ASA (OB:VISTIN), then you'll have to look at the makeup of its share registry. … With a market capitalization of øre341m, Vistin Pharma is a small cap stock, so it might not be well known by many institutional investors. … See our latest analysis for Vistin Pharma

Simply Wall St -

Is Vistin Pharma ASA (OB:VISTIN) A Financially Sound Company?

The direct benefit for Vistin Pharma ASA (OB:VISTIN), which sports a zero-debt capital structure, to include debt in its capital structure is the reduced cost of capital. … Does VISTIN's growth rate justify its decision for financial flexibility over lower cost of capital … There are well-known benefits of including debt in capital structure, primarily a lower cost of capital.

Simply Wall St -

Our Take On Vistin Pharma ASA's (OB:VISTIN) CEO Salary

This report will, first, examine the CEO compensation levels in comparison to CEO compensation at companies of similar size. … How Does Kjell-Erik Nordby's Compensation Compare With Similar Sized Companies. … At the time of writing our data says that Vistin Pharma ASA has a market cap of øre324m, and is paying total annual CEO compensation of øre5.3m.

Simply Wall St -

What Kind Of Investor Owns Most Of Vistin Pharma ASA (OB:VISTIN)?

A look at the shareholders of Vistin Pharma ASA (OB:VISTIN) can tell us which group is most powerful. … Taking a look at the our data on the ownership groups (below), it's seems that. … See our latest analysis for Vistin Pharma

Simply Wall St -

What Investors Should Know About Vistin Pharma ASA's (OB:VISTIN) Financial Strength

However, it also faces higher cost of capital given interest cost is generally lower than equity. … Is VISTIN right in choosing financial flexibility over lower cost of capital. … Debt capital generally has lower cost of capital compared to equity funding

Simply Wall St -

VISTIN Company Info

Description

Vistin Pharma ASA, through its subsidiary, Vistin Pharma AS, produces and sells metformin active pharmaceutical ingredients and direct compressible granulates for the pharmaceutical industry worldwide. Vistin Pharma ASA was founded in 2015 and is headquartered in Oslo, Norway.

Details
Name: Vistin Pharma ASA
VISTIN
Exchange: OB
Founded: 2015
NOK425,708,083
44,344,592
Website: http://www.vistin.com
Address: Vistin Pharma ASA
Østensjøveien 27,
Oslo,
Oslo, 0661,
Norway
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
OB VISTIN Ordinary Shares Oslo Bors NO NOK 10. Jun 2015
DB VP4 Ordinary Shares Deutsche Boerse AG DE EUR 10. Jun 2015
Number of employees
Current staff
Staff numbers
74
Vistin Pharma employees.
Industry
Pharmaceuticals
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/09/14 22:30
End of day share price update: 2019/09/13 00:00
Last estimates confirmation: 2018/02/27
Last earnings filing: 2019/08/29
Last earnings reported: 2019/06/30
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.